Safety, immunogenicity and clinical efficacy of an allergen vaccine (AllQbG10) in subjects with allergic rhino-conjunctivitis and asthma due to house dust mite allergy

Trial Profile

Safety, immunogenicity and clinical efficacy of an allergen vaccine (AllQbG10) in subjects with allergic rhino-conjunctivitis and asthma due to house dust mite allergy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2008

At a glance

  • Drugs CYT 005 AllQbG10 (Primary)
  • Indications Asthma; Rhinoconjunctivitis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 26 Apr 2008 New trial record.
    • 14 Dec 2005 Primary endpoint 'Immunological response' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top